Maximizing Potential: Essential Steps For Successful Commercialization Of Cell And Gene Therapies

Cell and gene therapy (CGT) products are revolutionizing the pharmaceutical industry by enabling treatment for millions of patients impacted by medical conditions that are untreatable with traditional medicines or surgeries such as certain cancers, inherited and rare diseases, and intractable conditions.

A growing number of these advanced therapies are advancing toward clinical trials and eventual commercialization. However, their unique manufacturing processes present significant challenges for biopharma manufacturers and can reduce patient access. Review the commercialization checklist to ensure that your therapy can advance to market with both a reduced risk of delays and additional costs as well as broad patient access.